IRD Opus Genetics, Inc.

NEUTRAL Impact: 5/10 8-K
Horizon months Filed Apr 24, 2026 Processed 1mo ago SEC 0001140361-26-016764
8-K context-dependent: Items 2.03
Latest settled — T+20d ⚠ clustered
IRD ▼ -20.12% at T+20d
NEUTRAL call ✗ call lost -20.12% · α vs SPY -25.07% · entry $5.12 → $4.09
Next anchor: T+60d in 5w
Currently $4.04 · -21.09% from $5.12 entry
Entry anchored
Apr 24, 03:59 PM ET
via Databento tick
T+1d
-2.34%
call -2.34% · α -1.86%
$5.00
settled 7w ago
T+5d
+1.95%
call +1.95% · α +1.55%
$5.22
settled 6w ago
T+20d
-20.12%
call -20.12% · α -25.07%
$4.09
settled 22d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Opus Genetics issued $35 million in senior secured notes as the first tranche of a $155 million financing facility. The notes mature in 2033, bear a floating interest rate based on Term SOFR, and are secured by substantially all company assets.

Actionable Insight

Monitor future tranches of this facility for additional funding draws, which could signal advancement of development milestones. The secured nature of the debt increases risk to existing equity holders if the company encounters financial difficulty.

Key Facts

  • Opus Genetics issued $35 million in senior secured notes on April 21, 2026
  • The notes are part of a larger $155 million facility, with $105 million committed and $50 million uncommitted
  • Notes mature on April 21, 2033, and bear interest at a floating rate based on Term SOFR plus a margin
  • Obligations are secured by substantially all assets of the company and its subsidiaries
  • Funding is subject to customary conditions and milestone achievements for future tranches

Financial Impact

$35 million in new debt issued, increasing leverage; total facility potential of $155 million

debtleveragecash flowinterest expense

Risk Factors

  • Increased leverage with secured debt could limit future financing options
  • Floating interest rate exposes the company to rate hike risk
  • Future draws on the facility may lead to additional dilution or restrictive covenants

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-016764
Document: 0001140361-26-016764-index-headers.html0001140361-26-016764
Document: 0001140361-26-016764-index.html0001140361-26-016764
Document: 0001140361-26-016764.txt0001140361-26-016764
12 reports for IRD
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IRD — sortable, filterable
Type Now
Jun 5, 2026
7d ago
S-3
BEARISH ★ 5/10
$4.61 awaiting T+5awaiting T+5$4.04 (+12.36%)
May 12, 2026
4w ago
8-K
MIXED ★ 5/10
$5.18 $4.44▼ −14.29%▼ −14.36%$4.04 (−22.01%)
May 12, 2026
4w ago
Press Release
BEARISH ★ 7/10
$5.18 $4.44▲ +14.29%▲ +14.36%$4.04 (+22.01%)
May 7, 2026
5w ago
Press Release
BULLISH ★ 6/10
$4.99 $4.97▼ −0.40%▼ −1.86%$4.04 (−19.04%)
Apr 24, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$5.12 $5.22▲ +1.95%▲ +1.55%$4.04 (−21.09%)
Apr 23, 2026
7w ago
EFFECT
NEUTRAL ★ 4/10
$5.21 $4.67▼ −10.36%▼ −11.84%$4.04 (−22.46%)
Apr 23, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$5.21 $4.67▼ −10.36%▼ −11.84%$4.04 (−22.46%)
Apr 10, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$5.36 $5.75▲ +7.28%▲ +2.77%$4.04 (−24.63%)
Apr 7, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$4.92 $5.55▲ +12.80%▲ +7.48%$4.04 (−17.89%)
Mar 16, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$5.19 $4.59▼ −11.56%▼ −9.52%$4.04 (−22.16%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (48h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access